TrialJournal of the Pediatric Infectious Diseases Society2026

Growth Outcomes After 48 Weeks of Dolutegravir in Children and Adolescents With HIV-1 in IMPAACT P1093 and IMPAACT 2019.

Michael McKenna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.